Drugs / Uridine
Uridine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02511041 | Jun 2015 → Jan 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00841269 | May 2009 → Jun 2013 | bipolar disorder | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00471614 | Apr 2007 → Jan 2012 | HIV infectious disease | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00322764 | Mar 2006 → ? | bipolar depression | Repligen Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00004658 | Mar 1995 → ? | 5-nucleotidase syndrome | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02640417 | Mar 2016 → Mar 2018 | — | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004705 | Sep 1996 → Jan 1999 | cystic fibrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT01261260 Comparator | Nov 2006 → Aug 2008 | — | Mclean Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00307164 Comparator | Sep 2006 → Dec 2008 | HIV infectious disease, localized lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT03265964 Comparator | Apr 2018 → Jun 2024 | — | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT01805440 Comparator | Aug 2013 → Dec 2015 | bipolar depression, manic bipolar affective disorder | University of Utah | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uridine | “A pilot trial showed that uridine (NucleomaxX) increased limb fat.” PMID 20827170 ↗ Oct 2010 |
| Known as | 1-.beta.-d-ribofuranosyluracil | ChEMBL registry synonym — accepted as the source's own label CHEMBL100259 ↗ |
| Known as | NSC-20256 | ChEMBL registry synonym — accepted as the source's own label CHEMBL100259 ↗ |
| Known as | NucleomaxX | “A pilot trial showed that uridine (NucleomaxX) increased limb fat.” PMID 20827170 ↗ Oct 2010 |
| Known as | RG2417 | “oral RG2417 (Uridine)” NCT00322764 ↗ |
| Known as | Uracil riboside | ChEMBL registry synonym — accepted as the source's own label CHEMBL100259 ↗ |
| Modality | Small molecule | “nucleoside supplement” NCT02511041 ↗ |
| Route | Oral | “36 g sachet taken orally three times daily” NCT00307164 ↗ |